Compounds Screening/Testing TRIZ Cases

A derivatized chitosan composition with a 15% to 40% degree of deacetylation crosslinked via EDC.

Conformation-specific antibodies target NUCB1-capped amyloid protofibrils to prevent beta-cell death in Type 2 diabetes.

Stimulating QRFP neurons reduces metabolic rate and body temperature to induce a hibernation-like state.

Segmenting the Amyloid Precursor Protein into specific marker peptides enables precise diagnosis and targeted therapy development.

Bivalirudin anticoagulant preserves bone marrow stem cell viability during rapid point-of-care processing.

In vitro models of human immunity assess vaccine interactions using transplanted human cells, reducing reliance on costly animal testing.

Specific polypeptides distinguish infected from vaccinated animals, resolving the specificity trade-off of crude PPD mixtures.

Splice modulating oligonucleotides alter RAGE pre-mRNA splicing patterns to shift isoform production.

Transcutaneous botulinum toxin delivery modulates cholinergic transmission to treat mood disorders.

Segmenting assessments using specific MXH and McH mouse strains identifies chromosome regions linked to drug toxicity.

Pre-conditioning with tetanus toxoid and CCL3 boosts dendritic cell homing, overcoming limited efficacy in advanced cancer immunotherapy.

Genetically engineered hamsters with knocked out LDL receptor genes exhibit elevated blood lipid levels suitable for cardiovascular studies.

Silencing Cxcl10 expression in engineered mice enables stable low-grade glioma xenograft modeling, overcoming premature senescence in existing models.

Transgenic flies harbor mutant kRAS to screen for inhibitors, resolving signaling complexity barriers in cancer drug discovery.

Aldehyde-binding compounds replace invasive tissue sampling by enabling non-invasive CEST-MRI detection of concussions and neurodegenerative disease markers.

Progranulin-derived peptides facilitate lysosomal enzyme trafficking across the blood-brain barrier to restore cellular function.

Specific amino acid substitutions in leptin antagonists boost binding affinity, enabling lower therapeutic doses while minimizing immunogenicity risks.

Engineered luciferase-expressing ovarian cancer cell lines emit bioluminescence to enable real-time visualization of tumor dynamics.

A non-human mammalian model expresses G-CSF to elevate neutrophil counts and inactivates DNase enzymes.

A colonoscopic capsule applies antigens to the colonic mucosa at a fixed depth using standardized penetration.

Engineered non-human animals with integrated human CCR8 genes mimic human immune responses to resolve the reliability-complexity trade-off in drug development.

Segmenting cell samples across multiple immunocompromised mice reduces assay time and animal usage while maintaining reliable follicle detection.

Specific epitope polypeptides differentiate infected from vaccinated animals, avoiding adjuvant sensitization and cross-reactivity.

Syngeneic subject screening identifies cancer cell modulators of immune responses using genetically modified cells.

Saline injection into spinal bone marrow spaces localizes leaks without radiation or contrast media side effects.

Specific phenotypic markers isolate multi-potent ILCPs while stromal intermediaries enable expansion, resolving precision versus complexity trade-offs.

A C. elegans reproductive disorder model enables high-throughput screening of genetically engineered probiotics.

A SERS substrate detects glucose via competitor molecule binding, resolving slow transdermal penetration and enzyme instability.

Mass spectrometry imaging visualizes molecule distribution within target tissue surfaces for rapid screening.

Resolves direct calcium measurement limits by quantifying manganese ion efflux through MEMRI imaging and pharmacokinetic modeling.

Crnn knockout mice replicate human psoriasis pathology, resolving inadequate animal model replication.

Rare earth metal-conjugated markers enable transcutaneous metabolite analysis via laser spectroscopy.

Ligating thoracic intercostal arteries creates a reproducible mouse model of ischemic injury, resolving the high cost and morbidity of large animal models.

Dynamic tetracycline control overcomes static knockout limitations, enabling reliable screening of therapeutic agents for psychiatric disorders.

Pre-determined proADM cut-off values enable rapid, objective therapy decisions at the point of care without requiring multiple sequential measurements.

Targeted ZC3H12B gene editing in medaka creates accurate intrahepatic cholangiocarcinoma models addressing hepatitis virus limitations.

A transgenic animal model with specific gene mutations predicts brain tumor tissue origin for targeted treatment.

An IL-31 antagonist molecule binds specifically to the cytokine polypeptide to inhibit biological activity.

A glioblastoma mouse model replicates parental tumor characteristics through orthotopic transplantation of dissociated cells.

An electrostatic skin patch binds allergen particles to deliver precise doses without invasive needles.

Engineered outer domain immunogens bind VRC01-class antibody precursors to prime affinity maturation pathways.

Plant-derived microvesicles encapsulate therapeutic agents, resolving the contradiction between scalable production and effective cellular targeting.

Intravenous L-lactate infusion assesses motor sign remission in patients with early Parkinson's disease symptoms.

Electrodes applying fast scanning cyclic voltammetry detect cardiac neurotransmitters, replacing invasive biopsies that carry infection risks.

TL1A transgenic mice enable targeted study of inflammatory bowel disease progression and fibrotic tissue development.

Fluorescent imaging detects changes in transplanted cells within the eye.

CCT2 binds ATG8 via an AIM motif to clear pathogenic solid aggregates, resolving non-specific ubiquitin binding side effects.

Viral vectors integrate gene perturbation constructs into hematopoietic stem cell genomes.